Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)
Amicus Therapeutics, Inc. (Nasdaq: FOLD) is back on investors’ radar as the rare-disease biotech extends a strong 2025 run—helped by a milestone quarter of GAAP profitability, expanding global launches for its Pompe franchise, and fresh news tied to a Phase
